Currently, three PAM inhibitors have received FDA approval for the treatment of HR+/HER2− advanced breast cancer (ABC) in combination with endocrine therapy: alpelisib (PI3Kα inhibitor), capivasertib (AKT inhibitor), and everolimus (mTORC1 inhibitor). Here, AKT1 is linked to breast carcinoma.